Accepting applications until August 1
Accepting applications until August 1
Ziting Wu , Yiwen Yu, Feng Xie, et al. BMC Health Serv Res. 2024 Sep 27;24(1): 1135
China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. This study aims to estimate the financial burden borne by patients and analyze the cost compositions of the leading cancers with th... Read More
Aug.Abdosaleh Jafari, Fatemeh A Hosseini, Faride S Jalali et al. Health Sci Rep. 2024 Aug 21;7(8):e70002
Colorectal cancer is the third most common cancer in the Western Hemisphere. It is the third most common cancer in men after prostate and lung cancers and the second most common cancer in women after breast cancer. According to so... Read More
Liam Rose, Ganesh Rajasekar , Anjali Nambiar , et al. JAMA Netw Open. 2025 Jul 1;8(7):e2521575
Cancer imposes a substantial economic burden on patients that may be worse in patients with higher-stage disease due to the need for more therapy. This retrospective cohort study used administrative claims data of a large national... Read More
Agnes Brandtmüller , Anne Meiwald , Peter Toth , et al. J Med Econ 2026 Dec;29(1):785-798
Cancer imposes a substantial clinical and economic burden across Europe. This analysis estimated the lost productivity cost of the five cancer types with the highest premature mortality and five cancer types with the highest morbi... Read More
November McGarvey, Matthew Gitlin, Ela Fadli,and Karen C. Chung. BMC Health Services Research (2022) 22:1155
Cancer represents a significant source of disease burden in the United States (US), both clinically and economically. Diagnosis and treatment of cancer at earlier stages may reduce this burden. To better understand potential impac... Read More
Allison W Kurian, Paul Abrahamse, Allison Furgal, et al. JAMA. 2023 Jul 3;330(1):43-51
Germline genetic testing is recommended by practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention. A... Read More
Danielle Brabender, Emily Siegel, Julie O. Culver, et al. Ann Surg Oncol (2025) 32:9041–9049
Only a subset of individuals meeting National Comprehensive Cancer Network (NCCN) guidelines for genetic screening of hereditary cancers are being offered testing. A total of 14,192 women were screened, with 3224 (23%) meeting NCC... Read More
The current method of BRCA testing for breast and ovarian cancer prevention, which is based on family history, often fails to identify many carriers of pathogenic variants. Population-based genetic testing offers a transformative... Read More
Alexandre Bolze, Elizabeth T. Cirulli, Catherine Hajek,. JAMA Oncol. 2024;10(2):236-239
Genetic information is not being used to identify women at lower risk of breast cancer or other diseases in clinical practice. With the new US Preventive Services Task Force guidelines lowering the age for mammogram screening for... Read More
Isabelle Bedrosian, Mark R. Somerfield, Maria Isabel Achatz, et al. J. Clin Oncol 2024 Feb 10;42(5):584-604
An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. Forty-seven articles met eligibility criteria for the germline mutation testing recomm... Read More
Joanne Kim, Andrew Harper, Valerie McCormack, et al. Nat Med. 2025 Apr;31(4):1154-1162.
Updates of current and projected estimates of the burden are critical to monitoring the success of ongoing efforts in breast cancer control, such as the World Health Organization Global Breast Cancer Initiative, which aims to redu... Read More
Tianyi Wang, Mandy Che, Yash S. Huilgol, et al. NPJ Breast Cancer | (2024) 10:90
Breast cancer risk reduction strategies have been well-validated, but barriers remain for high-risk individuals to adopt them. We performed a study among participants with high risk of breast cancer to validate whether a virtual b... Read More